Mirabegron: a guide to its use in overactive bladder syndrome in the EU

Abstract

Mirabegron (Betmiga TM ), a b 3 -adrenergic receptor agonist, is a useful option for the treatment of overactive bladder syndrome. In clinical trials in this patient population, oral mirabegron 50 mg once daily significantly reduced incontinence and micturition episodes, consistently reduced urgency episodes and increased the volume of urine voided per micturition, and was associated with improvements in health-related quality of life and treatment satisfaction. Mirabegron is generally well tolerated and is associated with less dry mouth than extendedrelease tolterodine.Adis evaluation of mirabegron 50 mg/day in overactive bladder syndrome Reduces incontinence, micturition and urgency episodes and increases the volume of urine voided per micturition Improves health-related quality of life and treatment satisfaction Generally well tolerated in adults with overactive bladder syndrome, including those aged C65 and C75 years